Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Self-Advocacy Platform Allows Patients with Autoimmune Diseases to Discover Triggers, Improve Disease ManagementDecember 6th 2022
Mymee, a self-advocacy platform, utilizes technological innovation, such as self-tracking, data analytics, and expert health coaching, to improve access and offer hope to these patients by uncovering their unique triggers, managing disease flares, and improving quality of life.
Patient Perspective: Support Program Helps Patients with Lupus Manage Their Disease, Improve QoLDecember 5th 2022
"Discovering your unique triggers can feel frustrating but with the right tools and support, it is possible to find answers," Hinton-Green emphasized. "You don’t have to do it alone."
Amy Mudano, MPH: Increasing COVID-19 Vaccine Uptake in Patients with Rheumatic DiseaseNovember 24th 2022
“These are people with autoimmune conditions who are taking immunomodulatory drugs that affect their immune system,” Mudano emphasized. “It's been shown that they may have worse outcomes if they do get COVID. So, it's important that they know that they really need this vaccine.”
Robert Maughan, PhD: Evaluating Treatment Cessation in Patients with Takayasu ArteritisNovember 23rd 2022
Although the ACR and EULAR have introduced guidelines for initial treatment of Takayasu Arteritis, Robert Maughan, PhD, explains that there is little to no data available to guide decisions.
Early Response to Guselkumab Linked to Long-Term Improvement in Health-Related QoL in PsANovember 22nd 2022
DISCOVER-2 is a phase 3, randomized, double-blind, multicenter study assessing the safety and efficacy of subcutaneous guselkumab treatment in biologic-naïve patients with active PsA.
Izokibep Treatment Improves Pain, Function in Patients with Active PsANovember 21st 2022
“The data continue to validate our hypothesis that izokibep offers differentiated efficacy with high potency and small size and reinforces izokibep’s potential to manage the hard-to-treat manifestations of PsA."
Philip Mease, MD: Guselkumab Effectively Treats Biologic-Naïve Patients with PsA and Axial InvolvementNovember 13th 2022
Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.
Daniel Hernandez, MD: Determining the Educational Needs of Hispanic Patients with RANovember 13th 2022
“It’s very possible to reach the Hispanic community and to go above and beyond what is currently being done, which is very little in terms of supporting them and giving them the tools that they need to create to have a better quality of life."